For its fourth fiscal quarter (ending December 31), Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has reported E.P.S. of $0.28 compared to $-0.26 a year ago. This result fell short of the consensus estimate of $0.31 by $-0.03. For the latest four quarters through December 31, E.P.S. were $-0.37 versus $-1.34 for the same period a year ago.
Recent Price Action
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock closed at $26.36 on 2/27/24 after an increase of 1.8%. Moreover, trading volume in this advance was above average at 133% of normal. The stock has risen 5.0% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, ACAD is expected to be a major Value Builder.
Acadia Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Acadia Pharmaceuticals has a very low Appreciation Score of 9 but a neutral Power Rating of 56, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment